RSV drug supply woes prompt White House team to meet with suppliers

The White House is pressing suppliers to meet the demand “with a sense of urgency” after drugmakers underestimated the demand for Beyfortus, the first respiratory syncytial virus drug for children.

Advertisement

Biden administration officials met with suppliers Nov. 27 to discuss how to move forward heading into winter, when RSV tends to increase. They also discussed planning for the second year of the monoclonal antibody drug’s rollout next fall, according to a Nov. 28 White House news release. 

The CDC released an additional 77,000 doses of Beyfortus on Nov. 16 to increase access after advising clinicians in late October to reserve the dwindling supplies for those most in need. 

“Monday’s meeting follows numerous in-person and virtual meetings to seek ways manufacturers can make more RSV immunizations available for infants,” the news release read. “CDC’s Vaccines for Children program provides vaccines to half of America’s children and senior administration officials will continue to work directly with distributors and manufacturers to make sure the RSV immunization, flu vaccine, and updated COVID-19 vaccine are available.”

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

From fragmentation to operational flow: Solving the healthcare workforce puzzle

Tuesday, August 11
1:00 PM - 2:00 PM CDT

Presenters: Dr. Pat Hunt, QGendaAndrea Daugherty, MHA, CISSP, CHCIO, CDH-E, Arrowhead Regional Medical CenterElizabeth Lindsay-Wood, MBA, CHCIO, CDH-E, Moffitt Cancer CenterDeb Muro, El Camino HealthJohn Tejeda, D.H.A., MLS, MPAS, DFAAPA, LSSBB, FACHE, Vascular and Neuroscience Institute

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.